BioSpace News Archive

Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL).

CG Oncology, Inc. today announced the closing of its upsized initial public offering of 23,000,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 3,000,000 additional shares.

NeoGenomics, Inc. today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024.

Can-Fite BioPharma Ltd today announced that it has expanded its out licensing transaction with Ewopharma AG. to include the pancreatic cancer indication of Can-Fite.

The interim analysis results from the phase III INSPIRE study of iruplinalkib developed by Qilu Pharmaceutical, which focuses on the first-line treatment of locally advanced or metastatic anaplastic lymphoma kinase -positive non-small cell lung cancer, have recently been featured in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

Enterprise Therapeutics Ltd announced that it has closed a £26 million Series B follow-on financing round, led by Panakes Partners.

COUR Pharmaceuticals announced the closing of a Series A investment round, securing approximately $105 million in financing.

ICON plc announced that it will release its financial results for the fourth quarter and full year 2023 results after the market closes on Wednesday, February 21, 2024.

Harmonic Discovery announced an exclusive licensing agreement of a novel small-molecule drug candidate for the treatment of FLT3 mutated acute myeloid leukemia from BioVentures and UC San Francisco.

Stryker reported operating results for the fourth quarter and full year of 2023: